Key points are not available for this paper at this time.
Enables scaled access to BILA 2157 BS for study; leaves open clinical efficacy in renin inhibition.
We have developed a convergent and stereoselective synthesis of orally active renin inhibitor BILA 2157 BS. Three building blocks were used to generate the basic skeleton of the inhibitor. The key feature consisted of the late elaboration of the 2-amino-4-thiazolyl heterocycle from a vinylbromide precursor. The synthetic sequence, which required a total of 22 chemical steps, provided 0.6 kg of BILA 2157 BS in 7.3% overall yield.
No takes yet. Share an insight, caveat, or question.
Simoneau et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: